"Reached later, an InKine spokesman said the company boosted its second quarter estimates because demand for the new Visicol was better than expected. April was the product's strongest month, capturing 8% of the market for prescription purgatives, he said.
The spokesman also said the company isn't taking the charge of 2 cents a share for the Visicol launch in the second quarter. The company had warned of the charge in April because it was concerned about large returns of the earlier formulation of Visicol. Instead, returns have been "modest" to this point, the spokesman said. The company plans to continue to monitor returns of the earlier formulation throughout the rest of the year. "